格隆汇12月26日丨嘉亨家化(300955.SZ)公布，公司接到控股股东曾本生先生通知，相关各方正在积极 推进本次交易的各项工作，整体方案仍在协商，交易各方尚未签署正式协议，公司预计无法在2025年12 月29日（星期一）上午开市起复牌。鉴于本次事项存在重大不确定性，为了维护投资者利益，避免对公 司股价造成重大影响，根据《深圳证券交易所创业板股票上市规则（2025年修订）》《深圳证券交易所 上市公司自律监管指引第6号——停复牌（2025年修订）》等有关规定，经公司向深圳证券交易所申 请，公司股票（证券简称：嘉亨家化，证券代码：300955）自2025年12月29日（星期一）开市起继续停 牌，预计停牌时间不超过3个交易日。 ...

Core Viewpoint - The company, Jiaheng Jiahua (300955.SZ), has announced that it will continue to suspend trading of its shares due to ongoing negotiations related to a significant transaction, which has not yet resulted in a formal agreement [1] Group 1 - The controlling shareholder, Mr. Zeng Bensheng, has notified the company that all parties involved are actively advancing the transaction [1] - The overall plan for the transaction is still under negotiation, and no formal agreement has been signed yet [1] - The company anticipates that it will not resume trading on December 29, 2025, as initially expected, due to the significant uncertainty surrounding the matter [1] Group 2 - To protect investor interests and avoid major impacts on the company's stock price, the company has applied to the Shenzhen Stock Exchange for an extension of the trading suspension [1] - The suspension of trading is expected to last no more than three trading days [1]

经公司向深圳证券交易所申请，公司股票自2025年12月29日(星期一)开市起继续停牌，预计停牌时间不 超过3个交易日。 智通财经APP讯，嘉亨家化(300955.SZ)发布公告，2025年12月26日，公司接到控股股东曾本生先生通 知，相关各方正在积极推进本次交易的各项工作，整体方案仍在协商，交易各方尚未签署正式协议，公 司预计无法在2025年12月29日(星期一)上午开市起复牌。 ...

Group 1 - The company, 嘉亨家化 (300955.SZ), announced that it received a notification from its controlling shareholder, 曾本生, regarding ongoing negotiations for a transaction, with no formal agreement signed yet [1] - The company expects to remain suspended from trading on the Shenzhen Stock Exchange starting December 29, 2025, due to the ongoing negotiations [1] - The anticipated suspension period is expected to not exceed three trading days [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300955 证券简称：嘉亨家化 公告编号：2025-039 嘉亨家化股份有限公司 关于筹划控制权变更事项进展暨继续停牌的公告 公司指定的信息披露媒体为《证券时报》《中国证券报》《证券日报》和巨 潮资讯网（http://www.cninfo.com.cn），公司所有信息均以在上述媒体刊登的公 告为准。 敬请广大投资者理性投资，注意投资风险。 特此公告。 嘉亨家化股份有限公司 一、停牌情况概述 嘉亨家化股份有限公司（以下简称"公司"）于 2025 年 12 月 24 日收到控股 股东曾本生先生的通知，获悉控股股东曾本生先生正在筹划控制权变更相关事宜， 该事项可能导致公司控股股东、实际控制人发生变更。经公司向深圳证券交易所 申请，公司股票（证券简称：嘉亨家化，证券代码：300955）自 2025 年 12 月 25 日（星期四）开市起停牌，预计停牌时间不超过 2 个交易日。具体内容详见 公司于 2025 年 12 月 24 日刊登在巨潮资讯网（http://www.cninfo.com.cn）上的《关 于筹 ...

Core Viewpoint - Jiaheng Jiahua is planning a change in control, leading to a temporary suspension of its stock trading, amid ongoing performance deterioration since the second generation took over a year ago [1][3][6]. Group 1: Control Change Announcement - On December 24, Jiaheng Jiahua announced that it would suspend trading of its stock starting December 25 due to a planned change in control [1][3]. - The controlling shareholder, Zeng Bensheng, is in discussions regarding the change, which may result in a shift in the company's actual controller [3][8]. Group 2: Stock Performance - On the announcement day, Jiaheng Jiahua's stock price surged over 13% during trading, closing at 41.51 yuan per share, with a market capitalization of 4.18 billion yuan [3][8]. - The stock has seen a year-to-date increase of 167% [3][8]. Group 3: Company Background - Jiaheng Jiahua specializes in OEM/ODM for daily chemical products and the design and production of plastic packaging containers, serving well-known global and domestic brands [3][8]. - The company went public on the Shenzhen Stock Exchange's Growth Enterprise Market in March 2021 [3][8]. Group 4: Management Transition - In November 2024, the company completed a board restructuring, with Zeng Bensheng stepping back and his son, Zeng Huanbin, becoming the chairman and continuing as general manager [3][8]. - Zeng Bensheng's daughter, Zeng Yapin, was appointed as vice chairman and vice general manager, marking the completion of the second-generation succession [3][8]. Group 5: Financial Performance - Jiaheng Jiahua has experienced continuous revenue decline, with revenues dropping by 9.45% in 2022 and 3.41% in 2023, while net profit fell by 28.25% and 42.39% respectively [4][9]. - In 2024, the company reported its first loss since going public, with a loss of 23.697 million yuan and a revenue decline of 9.13% [4][9]. - For the first three quarters of this year, the company achieved a revenue of 860 million yuan, a year-on-year increase of 24.42%, but reported a net loss of 29.5005 million yuan, exceeding the total loss of the previous year [10].

Core Viewpoint - The company, Jiaheng Jiahua, is undergoing a potential change in control as notified by its controlling shareholder, Zeng Bensheng, which may lead to a change in the company's actual controller [1]. Company Summary - Jiaheng Jiahua is primarily engaged in the research, design, and production of daily chemical products (OEM/ODM) and plastic packaging containers, providing integrated services for cosmetics and household care products [3]. - The company's main products include skincare, hair care, perfumes, soaps, disinfectants, and hand sanitizers, with major clients including well-known companies such as Kefu, Beitaini, and Procter & Gamble [4]. Financial Performance - In the first three quarters of 2025, Jiaheng Jiahua reported revenue of 859.6 million yuan, representing a year-on-year growth of 24.42%, but incurred a net loss of 29.5 million yuan [4]. - The cosmetics industry showed signs of recovery in 2025, despite a slight decline in growth compared to the overall retail sales of consumer goods [4].

Group 1 - Guangqi Technology's controlling shareholder proposed a share buyback of 50 million to 100 million yuan for employee stock ownership plans or equity incentives [1] - Xingyuan Zhuomai received a supplier designation from a domestic electric vehicle manufacturer to develop and supply reducer shell components, with expected sales of approximately 575 million yuan over four years from 2027 to 2030 [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Hongda Electronics disclosed uncertainty regarding the IPO progress of its associate Jiangsu Zhanxin, in which it holds a 13.79% stake [4] - Kangchen Pharmaceutical received FDA approval to conduct clinical trials for its KC1086 project, aimed at treating advanced recurrent or metastatic solid tumors [5] - Kweichow Moutai adjusted its share buyback price ceiling to 1863.67 yuan per share, effective from December 19, 2025 [6] Group 3 - Mousse Co. announced that its controlling shareholder and actual controllers committed not to reduce their holdings within one year [7] - Tongxingbao's subsidiary signed a business contract worth 43.166 million yuan for a cloud expansion project [8] - Kaifa Electric announced plans for three shareholders to collectively reduce their holdings by 0.6999% [9] Group 4 - Longpan Technology plans to increase the production capacity of lithium iron phosphate cathode materials from 62,500 tons per year to 100,000 tons per year [10] - Zhuhai Guanyu announced plans for two shareholders to reduce their holdings by up to 3% [11] - Jiaheng Home Textiles is planning a change in control, leading to a temporary suspension of its stock [12] Group 5 - Kehua Bio's subsidiary received a medical device registration certificate for a gene polymorphism detection kit [13] - Saitex New Materials' actual controller plans to reduce holdings by up to 3% [14] - Sanhui Electric announced a shareholder's plan to reduce holdings by up to 2% [15] Group 6 - Binhua Co. plans to establish a venture capital fund with a total scale of 400 million yuan, focusing on strategic emerging industries [16] - Jindun Co. announced plans for two shareholders to reduce their holdings by up to 4% [17] - Hengdian East Magnetic's controlling shareholder plans to reduce holdings by up to 1% [18][19] Group 7 - Luxin Investment's controlling shareholder plans to reduce holdings by up to 1% [20] - Huakang Clean announced a joint bid for a hospital procurement project worth 157 million yuan [21] - Xuedilong plans to reduce its repurchased shares by up to 488,560 shares [22] Group 8 - Enhua Pharmaceutical's subsidiary signed an exclusive commercial cooperation agreement for three long-acting antipsychotic products [23] - Aier Eye Hospital plans to acquire partial equity in 39 institutions for a total of 963 million yuan [24] - Gaozheng Mining plans to acquire 100% equity of Overseas Explosives for 510 million yuan [25] Group 9 - Donghong Co. plans to repurchase shares worth 30 million to 60 million yuan for employee stock ownership plans [26] - Bear Electric's controlling shareholder plans to reduce holdings by up to 0.64% [27] - *ST Zhengping announced the initiation of pre-restructuring by the Xining Intermediate Court [28][29] Group 10 - Caesar Travel's shareholder plans to reduce holdings by up to 3% [30] - Lianchuang Electronics announced a change in controlling shareholder to Jiangxi State-owned Assets Supervision and Administration Commission [31] - Beixin Road and Bridge plans to transfer 5.33% equity in Henan Yuhang for 243 million yuan [32] Group 11 - Fenglong Co. is planning a change in control, with stock resuming trading [33]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 停牌期间，公司将根据上述事项进展情况，严格按照有关法律法规的规定和要求履行信息披露义务。待 上述事项确定后，公司将及时发布相关公告并申请股票复牌。 公司指定的信息披露媒体为《证券时报》《中国证券报》《证券日报》和巨潮资讯网 （http://www.cninfo.com.cn），公司所有公开披露的信息以上述媒体刊登的信息为准。 敬请广大投资者理性投资，注意投资风险。 特此公告。 特别提示： 1、嘉亨家化股份有限公司（以下简称"本公司"、"公司"）控股股东曾本生先生正在筹划控制权变更相 关事宜，该事项可能导致公司控股股东、实际控制人发生变更。经公司向深圳证券交易所申请，公司股 票（证券简称：嘉亨家化，证券代码：300955）自2025年12月25日（星期四）开市起停牌，预计停牌时 间不超过2个交易日。 2、本次交易事项能否最终实施完成及实施结果尚存在不确定性，敬请广大投资者注意投资风险。 公司于2025年12月24日收到控股股东曾本生先生的通知，获悉控股股东曾本生先生 ...

Core Viewpoint - Jiahen Jiahua is planning a change in control, leading to a potential shift in its major shareholder and actual controller, with stock suspension starting from December 25, 2025, for up to two trading days [2] Group 1: Company Control Change - The company announced that its controlling shareholder, Zeng Bensheng, is in the process of planning a change in control, which may result in a change of the company's major shareholder and actual controller [2] - The matter is still in the planning stage, with significant uncertainty, and all parties are discussing specific plans and agreements [2] Group 2: Company Products and Clients - Jiahen Jiahua's product range includes skincare, hair care, perfumes, household care products like soap and disinfectants, and associated plastic packaging [2] - Major clients include well-known domestic and international brands such as Beitaini, Shanghai Jahwa, Yumaiting, Reckitt, Victoria's Secret, DoTerra, Procter & Gamble, Johnson & Johnson, and Shell [2] Group 3: Leadership Transition - In November 2024, Zeng Bensheng was granted the title of honorary chairman for life and stepped down from his roles as chairman and legal representative, with his son, Zeng Huanbin, taking over [2] - Zeng Bensheng's daughter, Zeng Yaping, has also joined the board as vice general manager and vice chairman, marking the official transition to the "second generation" leadership [3] Group 4: Financial Performance - For the first three quarters of 2025, Jiahen Jiahua reported revenue of 860 million yuan, a year-on-year increase of 24.42%, but a net profit loss of 29.5 million yuan, a dramatic decline of 1430.74% [3] - This marks the first loss in net profit attributable to the parent company in the first three quarters over the past five years [3] Group 5: Reasons for Profit Decline - The significant decline in net profit is attributed to changes in product sales structure and increased fixed costs from depreciation and amortization at Huzhou Jiahen [5] - Increased management expenses due to higher employee compensation and rising interest expenses from expanded bank loans have also contributed to the increase in period costs [5] Group 6: Stock Market Reaction - On December 24, 2025, Jiahen Jiahua's stock price surged, increasing by over 13% at one point, and closing up 8.32% at 41.51 yuan per share, with a total market value of 4.184 billion yuan [6]